CA2383321A1 - Promoteur specifique des cellules musculaires lisses, et utilisations associees - Google Patents
Promoteur specifique des cellules musculaires lisses, et utilisations associees Download PDFInfo
- Publication number
- CA2383321A1 CA2383321A1 CA002383321A CA2383321A CA2383321A1 CA 2383321 A1 CA2383321 A1 CA 2383321A1 CA 002383321 A CA002383321 A CA 002383321A CA 2383321 A CA2383321 A CA 2383321A CA 2383321 A1 CA2383321 A1 CA 2383321A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- cell
- delivery vehicle
- smooth muscle
- adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne de nouveaux promoteurs spécifiques des cellules musculaires lisses et leurs utilisations. Ces promoteurs permettent de conférer à un acide nucléique considéré la capacité de s'exprimer spécifiquement dans une cellule musculaire lisse contractile, de préférence une cellule musculaire lisse contractile vasculaire et/ou une cellule musculaire lisse contractile viscérale. Un exemple de ce type de promoteur est un promoteur du gène smootheline, dérivé, de préférence d'un être humain. Le promoteur selon l'invention peut être incorporé dans un vecteur d'acide nucléique. Ce vecteur d'acide nucléique comprend, de préférence, une particule du type virus, notamment une particule d'adénovirus, un particule de virus adéno-associé ou une particule de rétrovirus.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15328499P | 1999-09-09 | 1999-09-09 | |
EP9920943.9 | 1999-09-09 | ||
US60/153,284 | 1999-09-09 | ||
EP99202943A EP1083231A1 (fr) | 1999-09-09 | 1999-09-09 | Promoteur spécifique des cellules musculaires lisses, et applications |
PCT/NL2000/000638 WO2001018048A2 (fr) | 1999-09-09 | 2000-09-08 | Promoteur specifique des cellules musculaires lisses, et utilisations associees |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2383321A1 true CA2383321A1 (fr) | 2001-03-15 |
Family
ID=8240624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002383321A Abandoned CA2383321A1 (fr) | 1999-09-09 | 2000-09-08 | Promoteur specifique des cellules musculaires lisses, et utilisations associees |
Country Status (5)
Country | Link |
---|---|
US (1) | US20030157494A1 (fr) |
EP (2) | EP1083231A1 (fr) |
AU (1) | AU7459600A (fr) |
CA (1) | CA2383321A1 (fr) |
WO (1) | WO2001018048A2 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7101565B2 (en) | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
DE102004020934B4 (de) * | 2004-04-28 | 2007-01-04 | Tyco Electronics Amp Gmbh | Stecker mit einem Sicherungselement mit integriertem Dämpfungselement |
US20050277124A1 (en) | 2004-06-10 | 2005-12-15 | White Steven M | Cardiac conduction system cells and uses thereof |
CN101868241A (zh) | 2007-09-28 | 2010-10-20 | 英特瑞克斯顿股份有限公司 | 表达生物治疗分子的治疗基因开关构建物和生物反应器以及它们的应用 |
GEP20217251B (en) | 2012-05-25 | 2021-04-26 | Charpentier Emmanuelle De Emanuel | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
US20160298096A1 (en) | 2013-11-18 | 2016-10-13 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
WO2015089277A1 (fr) | 2013-12-12 | 2015-06-18 | The Regents Of The University Of California | Procédés et compositions pour modifier un acide nucléique cible monobrin |
US10800830B2 (en) | 2014-08-08 | 2020-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity PD-1 agents and methods of use |
EP3268472B1 (fr) | 2015-03-13 | 2021-05-05 | The Jackson Laboratory | Système de complexe cas/crispr à trois constituants et utilisations de ce dernier |
EP3303634B1 (fr) | 2015-06-03 | 2023-08-30 | The Regents of The University of California | Variants de cas9 et procédés d'utilisation associés |
US20180142222A1 (en) | 2015-06-12 | 2018-05-24 | The Regents Of The University Of California | Reporter cas9 variants and methods of use thereof |
AU2016339053A1 (en) | 2015-09-24 | 2018-04-12 | Crispr Therapeutics Ag | Novel family of RNA-programmable endonucleases and their uses in genome editing and other applications |
WO2017155408A1 (fr) | 2016-03-11 | 2017-09-14 | Erasmus University Medical Center Rotterdam | Outil d'édition génomique crispr-cas9 amélioré |
US20200291368A1 (en) | 2016-03-11 | 2020-09-17 | Wageningen Universiteit | Improved CRISPR-Cpf1 Genome Editing Tool |
MA50579A (fr) | 2017-11-09 | 2020-09-16 | Crispr Therapeutics Ag | Systèmes crispr/cas ou crispr/cpf1 à auto-inactivation (sin) et leurs utilisations |
WO2019118935A1 (fr) | 2017-12-14 | 2019-06-20 | Casebia Therapeutics Limited Liability Partnership | Nouveaux systèmes d'endonucléases arn-programmables et leurs utilisations dans l'édition de génome et d'autres applications |
JP2021518139A (ja) | 2018-03-19 | 2021-08-02 | クリスパー セラピューティクス アーゲー | 新規rnaプログラム可能エンドヌクレアーゼ系およびその使用 |
EP3886759A1 (fr) | 2018-11-26 | 2021-10-06 | Massachusetts Institute of Technology | Compositions et procédés pour induire une tolérance immunitaire |
SG11202109741VA (en) | 2019-03-12 | 2021-10-28 | Crispr Therapeutics Ag | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
WO2020225606A1 (fr) | 2019-05-08 | 2020-11-12 | Crispr Therapeutics Ag | Systèmes de vecteurs crispr/cas en deux parties pour le traitement de dmd |
WO2021016075A1 (fr) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Compositions à recombinase et leurs méthodes d'utilisation |
US20230295615A1 (en) | 2020-08-07 | 2023-09-21 | The Jackson Laboratory | Targeted Sequence Insertion Compositions and Methods |
EP4101928A1 (fr) | 2021-06-11 | 2022-12-14 | Bayer AG | Systèmes d'endonucléase programmables à arn de type v |
EP4352214A1 (fr) | 2021-06-11 | 2024-04-17 | Bayer AG | Systèmes d'endonucléase programmables par l'arn de type v |
EP4144841A1 (fr) | 2021-09-07 | 2023-03-08 | Bayer AG | Nouveaux systèmes d'endonucléase programmables à petit arn à spécificité pam améliorée et leurs utilisations |
EP4399292A2 (fr) | 2021-09-08 | 2024-07-17 | Flagship Pioneering Innovations VI, LLC | Procédés et compositions pour moduler un génome |
WO2023118068A1 (fr) | 2021-12-23 | 2023-06-29 | Bayer Aktiengesellschaft | Nouveaux petits systèmes programmables d'endonucléases à arn de type v |
WO2023237587A1 (fr) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Nouveaux petits systèmes programmables d'endonucléases à arn de type v |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090618A (en) * | 1996-10-07 | 2000-07-18 | Arch Development Corporation | DNA constructs and viral vectors comprising a smooth muscle promoter |
-
1999
- 1999-09-09 EP EP99202943A patent/EP1083231A1/fr not_active Withdrawn
-
2000
- 2000-09-08 WO PCT/NL2000/000638 patent/WO2001018048A2/fr not_active Application Discontinuation
- 2000-09-08 EP EP00963146A patent/EP1214439A2/fr not_active Withdrawn
- 2000-09-08 CA CA002383321A patent/CA2383321A1/fr not_active Abandoned
- 2000-09-08 AU AU74596/00A patent/AU7459600A/en not_active Abandoned
-
2002
- 2002-03-08 US US10/094,516 patent/US20030157494A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030157494A1 (en) | 2003-08-21 |
EP1214439A2 (fr) | 2002-06-19 |
WO2001018048A2 (fr) | 2001-03-15 |
WO2001018048A3 (fr) | 2001-08-02 |
AU7459600A (en) | 2001-04-10 |
EP1083231A1 (fr) | 2001-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1083231A1 (fr) | Promoteur spécifique des cellules musculaires lisses, et applications | |
AU666142B2 (en) | Viral recombinant vectors for expression in muscle cells | |
JP4981229B2 (ja) | ハイブリッド血管内皮成長因子DNAsおよびタンパク質に関与する物質および方法 | |
JP3457332B2 (ja) | 平滑筋細胞発現のためのプロモーター | |
AU773202B2 (en) | Targeted adenovirus vectors for delivery of heterologous genes | |
JPH08501703A (ja) | 欠陥組換えアデノウイルスベクター及び遺伝子治療での使用 | |
US20100311161A1 (en) | Method for tissue regeneration | |
KR100575521B1 (ko) | 재조합 아데노 바이러스 게놈의 제조 방법 | |
JPH10507927A (ja) | 改良されたアデノウイルスおよびその使用法 | |
JPH10507079A (ja) | 治療遺伝子と免疫保護遺伝子とを含む欠陥アデノウイルス | |
JP2002507391A5 (fr) | ||
JPH09511240A (ja) | 動脈平滑筋細胞増殖の抑制 | |
EP2855685B1 (fr) | Vecteurs adénoviraux pour la transduction du tissu vasculaire | |
JPH11503011A (ja) | 条件発現系 | |
Baldwin et al. | Adenovirus-mediated gene transfer during initial organogenesis in the mammalian embryo is promoter-dependent and tissue-specific | |
AU770005B2 (en) | Selective regulation of adenovirus production | |
JP2001521387A (ja) | アポトーシス誘発タンパク質vp2および/またはアポプチンを発現する遺伝子伝達体 | |
CA2398842A1 (fr) | Vecteurs adenovirus deficients pour la replication | |
JP2000500017A (ja) | 遺伝子治療核酸構造体、その製造と心臓疾患治療へのその利用 | |
JP2000157289A (ja) | 平滑筋細胞および/または内皮細胞への組織向性を与えられた遺伝子送達ベクタ― | |
US7368553B2 (en) | Alternatively spliced nucleic acid molecules | |
JP2002525109A (ja) | 組織発現を調節するための特異的ハイブリッドプロモーターの使用 | |
WO2003006621A2 (fr) | Super agent promoteur de l'osteocalcine pour traiter les tumeurs calcifiees et les tissus calcifies | |
AU7164000A (en) | Nucleic acid sequences of genes of the high mobility group proteins and their use | |
FR2783839A1 (fr) | Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |